ESC 365 - Discussant review:Apixaban vs conventional therapy in anticoagulation-naive patients with atrial fibrillation undergoing cardioversion: The EMANATE Trial

ESC Premium Access

Discussant review:Apixaban vs conventional therapy in anticoagulation-naive patients with atrial fibrillation undergoing cardioversion: The EMANATE Trial

Session: Hot Line: Late-Breaking Clinical Trials 2

Topic: Atrial fibrillation (AF)

Speaker: Professor J. Nielsen (Aarhus, DK)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Professor Jens Cosedis Nielsen

Aarhus University Hospital, Aarhus (Denmark)

26 presentations

10 followers

17 more presentations in this session

SPYRAL HTN OFF-MED Study

Speaker: Professor M. Boehm (Homburg, DE)

Discussant review: SPYRAL HTN OFF-MED Study

Speaker: Professor B. Williams (London, GB)

Panel discussion.

Apixaban vs conventional therapy in anticoagulation-naive patients with atrial fibrillation undergoing cardioversion: The EMANATE Trial

Speaker: Professor M. Ezekowitz (Philadelphia, US)

Panel discussion.

Access the full session

Hot Line: Late-Breaking Clinical Trials 2

Speakers: Professor J. Nielsen, Professor M. Boehm, Professor B. Williams, Professor M. Ezekowitz

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources